Delayed response to ipilimumab therapy

This patient with metastatic melanoma had no discernible disease in the liver at baseline. After four doses of ipilimumab, numerous lesions were apparent, classically considered progression. However, two months later, without drug, these lesions regressed. After four additional doses of ipilimumab, the patient had a complete response.